NCT02215499View on ClinicalTrials.gov

A Phase 1, Single Dose Study of JZP-386 to Evaluate Safety, Pharmacokinetics and Pharmacodynamics

PHASE1CompletedINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

July 31, 2014

Primary Completion Date

November 30, 2014

Study Completion Date

November 30, 2014

Conditions
Narcolepsy, Excessive Daytime Sleepiness
Interventions
DRUG

Placebo

DRUG

Sodium Oxybate

DRUG

JZP-386

Trial Locations (1)

NG11 6JS

Quotient Clinical Ltd., Ruddington

Sponsors
All Listed Sponsors
lead

Concert Pharmaceuticals

INDUSTRY

NCT02215499 - A Phase 1, Single Dose Study of JZP-386 to Evaluate Safety, Pharmacokinetics and Pharmacodynamics | Biotech Hunter | Biotech Hunter